Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy

Related Experiment Video

Updated: Aug 25, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Rubina A Heptulla1, Holley F Allen, Todd M Gross

  • 1Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030-2399, USA. raheptul@texaschildrenhospital.org

Pediatric Diabetes
|March 27, 2004
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) therapy significantly improved glycemic control in children with type 1 diabetes mellitus (T1DM). Insulin pump use reduced HbA1c and postprandial glucose excursions, particularly after meals.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes mellitus (T1DM) requires intensive management to mimic physiologic insulin secretion.
  • Continuous subcutaneous insulin infusion (CSII) therapy aims to optimize glycemic control in T1DM patients.
  • Understanding specific improvements from CSII is crucial for treatment efficacy.

Purpose of the Study:

  • To evaluate the impact of CSII on glycemic control in pediatric T1DM patients.
  • To identify specific times and parameters of glucose control that improve with insulin pump therapy.
  • To assess the need for further adjustments in CSII therapy.

Main Methods:

  • Eight pediatric patients (7.5-17 years) with T1DM participated.
  • Continuous Glucose Monitoring System (CGMS) was used for 3 days before and 3 months after CSII initiation.
  • Data collected included interstitial glucose, food intake, exercise, and hypoglycemia logs.

Main Results:

  • Hemoglobin A1c (HbA1c) levels significantly decreased (p < 0.007) after 3 months of CSII.
  • Hourly mean glucose levels improved over 24 hours (p < 0.001).
  • Maximal postprandial glycemic excursions were significantly attenuated after meals (post-breakfast, -lunch, -dinner).

Conclusions:

  • Insulin pump therapy (CSII) effectively improved glycemic control in children with T1DM.
  • CSII specifically reduced postprandial glucose spikes, indicating better mealtime glucose management.
  • Further research may focus on refining CSII parameters for even greater control.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...